市場調查報告書
商品編碼
1028281

中國的Exemestane市場(2021年∼2025年)

Research Report on China's Exemestane Market, 2021-2025

出版日期: | 出版商: China Research and Intelligence | 英文 40 Pages | 商品交期: 最快1-2個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

Pharmacia & Upjoin 的Exemestane直到2008年才被導入中國市場,當時中國本土公司的幾種仿製藥已經在中國上市。2002年Pharmacia & Upjoin的Exemestane(商品名AROMASIN®)在中國市場極具競爭力,2020年銷售額佔中國Exemestane市場的90%以上。儘管2020年初COVID-19疫情對中國醫療保健產業產生了影響,但Exemestane在中國市場的銷售額在2020年繼續成長,達到約4億元人民幣(6160萬美元),從2016年到2020年年複合成長率為 9.2%。

本報告提供中國的Exemestane市場的相關調查,市場規模和預測,市場動態,COVID-19的影響,開發環境,廠商及市場佔有率,銷售價格等資訊。

目錄

第1章 Exemestane的相關概念

  • Exemestane的適應症
  • 中國的Exemestane市場發展
  • 中國的Exemestane的政府核准
  • COVID-19對中國的Exemestane市場的影響

第2章 中國的Exemestane銷售(2016-2020)

  • 銷售額
    • 中國的銷售額
    • 各地區:中國的銷售額
  • 銷售量
    • 中國的銷售量
    • 各地區:中國的銷售量
  • 各劑型:中國的Exemestane銷售(2016-2020)
    • 錠劑
    • 膠囊

第3章 中國的主要Exemestanemeka分析(2020)

  • 市場佔有率分析
    • 各銷售額製造商市場佔有率
    • 各銷售量製造商市場佔有率
  • Pharmacia & Upjohn SpA
    • 企業簡介
    • 中國的Exemestane銷售
  • Qilu Pharmaceutical Co., Ltd.
    • 企業簡介
    • 中國的Exemestane銷售
  • Hainan Tongyong Tongmeng Pharmaceutical Co., Ltd.
    • 企業簡介
    • 中國的Exemestane銷售
  • Tongfang Pharmaceutical Group Co., Ltd.
    • 企業簡介
    • 中國的Exemestane銷售

第4章 各企業的中國的Exemestane銷售價格(2020-2021)

  • Pharmacia & Upjohn SpA (AROMASIN (R))
  • Qilu Pharmaceutical Co., Ltd. (SuLai (R))
  • Hainan Tongyong Tongmeng Pharmaceutical Co., Ltd. (YiSiTan (R))
  • Tongfang Pharmaceutical Group Co., Ltd. (YouKeYi (R))

第5章 中國的Exemestane市場預測(2021-2025)

  • 市場開發的影響因素
    • COVID-19對市場的影響
    • 市場成長要素和機會
    • 市場威脅與課題
  • 市場規模的預測
  • 市場趨勢的預測
目錄
Product Code: 2109555

Breast cancer is a common malignant tumor in menopausal women, and now ranks first among malignant tumors in women. Recently, the number of breast cancer patients in China has been increasing year by year, with 420,000 new cases and 120,000 deaths in China in 2020. Breast cancer has become a malignant tumor that seriously endangers women's health. Hormone therapy is a widely accepted treatment, especially for the treatment of estrogen receptor positive tumors. Aromatase inhibitors offer a new option for hormone therapy. Exemestane, an irreversible steroidal aromatase inactivator, significantly reduces circulating levels of estrogen in menopausal women by irreversibly binding to the active site of the enzyme and inactivating it, thus achieving an anti-tumor effect.

Exemestane is a third-generation aromatase inhibitor originally developed by Pharmacia & Upjoin (now a subsidiary of Pfizer). It was first approved in the UK in April 1999 and has been marketed in several countries for clinical use in the treatment of advanced breast cancer in postmenopausal women. Exemestane tablets are an effective and selective treatment for postmenopausal hormone-dependent breast cancer. Exemestane tablets, as third-generation aromatase inhibitors, are with strong selectivity and long-lasting effects. They can also control breast cancer growth by inhibiting aromatase and blocking estrogen production.

According to CRI's market research, Pharmacia & Upjoin's exemestane was not introduced into the Chinese market until 2008, when several generic drugs from local Chinese companies were already available in the Chinese market, of which the exemestane tablets from Qilu Pharmaceutical was already marketed in China in 2002. Pharmacia &Upjoin's exemestane (trade name AROMASIN®) is extremely competitive in the Chinese market, accounting for more than 90% of China's exemestane market in 2020 in terms of sales value. Despite the impact of the COVID-19 outbreak on the Chinese healthcare industry in early 2020, the sales value of exemestane in the Chinese market continued to grow in 2020, reaching approximately CNY400 million (USD61.6 million), with a CAGR of 9.2% from 2016 to 2020.

Breast cancer has replaced lung cancer as the number one cancer worldwide due to the rapid growth in the number of new cases in 2020. The increasing breast cancer cases are fundamentally caused by the altering risk factors for breast cancer, such as changing lifestyles and notions of marriage and childbearing due to economic growth, namely a general rise in the age of women having children, a decrease in the average number of births, overweight, obesity and lack of exercise, all contributing to the increase in the incidence of breast cancer. CRI expects that from 2021 to 2025, new cases of breast cancer in China will continue to grow, resulting in increases in both sales volume and value of exemestane in the Chinese market.

Topics Covered:

Impact of COVID-19 on China's Exemestane Market

Development Environment of Exemestane in China

Sales Volume of Exemestane in China

Sales Volume and Value of Exemestane in China by Region

Major Exemestane Manufacturers in China and Their Market Shares

Sales Price of Exemestane in China

Prospects of China's Exemestane Market, 2021-2025

Table of Contents

1 Relevant Concept of Exemestane

  • 1.1 Indications of Exemestane
  • 1.2 Development of China's Exemestane Market
  • 1.3 Governmental Approval of Exemestane in China
  • 1.4 The Impact of COVID-19 on China's Exemestane Market

2 Sales of Exemestane in China, 2016-2020

  • 2.1 Sales Value
    • 2.1.1 Sales Value in China
    • 2.1.2 Sales Value in China by Region
  • 2.2 Sales Volume
    • 2.2.1 Sales Volume in China
    • 2.2.2 Sales Volume in China by Region
  • 2.3 Sales of Exemestane in China by Dosage Form, 2016-2020
    • 2.3.1 Tablets
    • 2.3.2 Capsules

3 Analysis of Major Exemestane Manufacturers in China, 2020

  • 3.1 Analysis of Market Share
    • 3.1.1 Market Share of Manufacturers by Sales Value
    • 3.1.2 Market Share of Manufacturers by Sales Volume
  • 3.2 Pharmacia & Upjohn SpA
    • 3.2.1 Company Profile
    • 3.2.2 Sales of Exemestane in China
  • 3.3 Qilu Pharmaceutical Co., Ltd.
    • 3.3.1 Company Profile
    • 3.3.2 Sales of Exemestane in China
  • 3.4 Hainan Tongyong Tongmeng Pharmaceutical Co., Ltd.
    • 3.4.1 Company Profile
    • 3.4.2 Sales of Exemestane in China
  • 3.5 Tongfang Pharmaceutical Group Co., Ltd.
    • 3.5.1 Company Profile
    • 3.5.2 Sales of Exemestane in China

4 Sales Price of Exemestane of Different Companies in China, 2020-2021

  • 4.1 Pharmacia & Upjohn SpA (AROMASIN®)
  • 4.2 Qilu Pharmaceutical Co., Ltd. (SuLai®)
  • 4.3 Hainan Tongyong Tongmeng Pharmaceutical Co., Ltd. (YiSiTan®)
  • 4.4 Tongfang Pharmaceutical Group Co., Ltd. (YouKeYi®)

5 Prospects of China's Exemestane Market, 2021-2025

  • 5.1 Influencing Factors for the Market Development
    • 5.1.1 The Impact of COVID-19 on the Market
    • 5.1.2 Market Drivers and Opportunities
    • 5.1.3 Market Threats and Challenges
  • 5.2 Forecast on Market Size
  • 5.3 Forecast on Market Trend

List of Charts

  • Chart Patent Information of Exemestane in China
  • Chart Sales Value of Exemestane in China, 2016-2020
  • Chart Sales Volume of Exemestane in China, 2016-2020
  • Chart Sales of Exemestane Tablets in China, 2016-2020
  • Chart Sales of Exemestane Capsules in China, 2016-2020
  • Chart Sales Volume of Exemestane in China by Region, 2016-2020
  • Chart Sales Value of Exemestane in China by Region, 2016-2020
  • Chart Market Share of Exemestane Manufacturers in China by Sales Value, 2016-2020
  • Chart Sales Value and Volume of AROMASIN (Exemestane of Pharmacia & Upjohn SpA) in China, 2016-2020
  • Chart Sales Value and Volume of Exemestane (of Qilu Pharmaceutical Co., Ltd.) in China, 2016-2020
  • Chart Sales Price of Exemestane (of Pharmacia & Upjohn SpA) in China by Region, 2020
  • Chart Sales Price of SuLai (Exemestane of Qilu Pharmaceutical Co., Ltd.) in China by Region, 2020
  • Chart Forecast on Sales Value of Exemestane in China, 2021-2025
  • Chart Forecast on Sales Volume of Exemestane in China, 2021-2025